Fenwick Represents Synthego in the Sale of its Engineered Cell Solutions Business to EditCo Bio

Fenwick is representing Synthego, a provider of genome engineering solutions, in the sale of its engineered cell solutions and enhanced guide RNA business to EditCo Bio.

Synthego’s engineered cell solutions and enhanced guide RNA business will serve as the foundation for the new launched EditCo Bio, which will concentrate on the development and manufacturing of CRISPR guide RNA designs and offer edited cells to researchers. EditCo Bio will operate as an independent business and will be led by former Synthego President and Chief Operating Officer John Tan, with financial support from Telegraph Hill Partners. More information can be obtained from Synthego’s announcement.

The Fenwick transaction team includes corporate partners Ethan Skerry and Steven Levine, counsel Brian Hicks and associates Zachary Portnoy, Jiarui Li, David Heckman, Zoe Zhang and Brandon Ho; technology transactions partner Stefano Quintini, associates Pinar Bailey, Trevor Snider and Ju Yun (Julie) Son; executive compensation and employee benefits partner Matt Cantor and associate Jonathan Stephenson; and tax partner Mike Knobler and associate Kris Hatch.